Talia Golan

Talia Golan

Ramat Gan, TA 52621, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 135 publications

Histologic spectrum of BRCA-associated pancreatic ductal adenocarcinoma: A descriptive morphologic study.

Histologic spectrum of BRCA-associated pancreatic ductal adenocarcinoma: A descriptive morphologic study.

Journal: Human pathology
Published: April 15, 2026

Histologic Spectrum of BRCA-Associated Pancreatic Ductal Adenocarcinoma : A Descriptive Morphologic Study.

Histologic Spectrum of BRCA-Associated Pancreatic Ductal Adenocarcinoma : A Descriptive Morphologic Study.

Journal: Human pathology
Published: April 15, 2026

Exploring per-base quality scores as a surrogate marker of cell-free DNA fragmentome.

Exploring per-base quality scores as a surrogate marker of cell-free DNA fragmentome.

Journal: Briefings in bioinformatics
Published: March 20, 2026

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2025

Exploring pancreatic variability in BRCA carriers vs. Non-Carriers: A diffusion tensor MRI study.

Exploring pancreatic variability in BRCA carriers vs. Non-Carriers: A diffusion tensor MRI study.

Journal: European journal of radiology
Published: July 20, 2025

Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection.

Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection.

Journal: Journal of clinical medicine
Published: June 01, 2025

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Journal: Cell reports. Medicine
Published: March 03, 2025

Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Therapy.

Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Therapy.

Journal: Annals of surgical oncology
Published: January 16, 2025

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Journal: Frontiers in oncology
Published: December 12, 2024

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2024

A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.

A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.

Journal: CA: a cancer journal for clinicians
Published: September 09, 2024

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2024
Showing 1-12 of 135

Last Updated: 09/26/2026